Rubius Therapeutics to Announce Second Quarter 2019 Financial Results

CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced plans to report second quarter 2019 financial results on Tuesday, August 13, 2019, before market open.

The company will not be conducting a teleconference in conjunction with its financial results press release.

About Rubius Therapeutics

Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM^® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. For more information, visit www.rubiustx.com, or follow us on Twitter and LinkedIn.

Contact:
Lori Melançon
Vice President, Corporate Communications and Investor Relations
+1 (617) 949-5296
[email protected]

Media Contact: 
Dan Budwick
1AB
+1 (973) 271-6085
[email protected]

You May Also Be Interested In

• Intel (INTC) PT Lowered to $92 at Mizuho
• PacBio to Participate in the Morgan Stanley 24ᵗʰ Annual Global Healthcare Conference
• NorthStrive® Companies Inc. Announces New Brand Identity and Establishes Trademark Licensing Strategy